Product Description
a selective TGR5 agonist, SB-756050, for patients with T2D (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27121782/)
Mechanisms of Action: TGR5 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00733577 |
NCT00733577 | P1 |
Completed |
Type 2 Diabetes |
2009-03-03 |
2019-03-18 |
Treatments |
|
NCT00607906 |
AXO110461 | P1 |
Completed |
Type 2 Diabetes |
2008-03-10 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|